NO20021976L - Selective liver therapy - Google Patents

Selective liver therapy

Info

Publication number: NO20021976L
Authority: NO; Norway
Prior art keywords: liver therapy; selective liver; selective; therapy; liver
Prior art date: 1999-11-03

Application number

NO20021976A

Other languages

Norwegian (no)

Other versions

NO20021976D0 (en

Inventor

Howard J Smith

Original Assignee

Smith Howard J & Ass Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-03

Filing date

2002-04-25

Publication date

2002-06-19

1999-11-03 Priority claimed from AUPQ3855A external-priority patent/AUPQ385599A0/en

2000-01-24 Priority claimed from AUPQ5236A external-priority patent/AUPQ523600A0/en

2000-02-07 Priority claimed from AUPQ5471A external-priority patent/AUPQ547100A0/en

2002-04-25 Application filed by Smith Howard J & Ass Pty Ltd filed Critical Smith Howard J & Ass Pty Ltd

2002-04-25 Publication of NO20021976D0 publication Critical patent/NO20021976D0/en

2002-06-19 Publication of NO20021976L publication Critical patent/NO20021976L/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

NO20021976A 1999-11-03 2002-04-25 Selective liver therapy NO20021976L (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
AUPQ3855A AUPQ385599A0 (en)	1999-11-03	1999-11-03	Treatment of hypercholesterolaemia
AUPQ5236A AUPQ523600A0 (en)	2000-01-24	2000-01-24	Treatment of portal hypertension
AUPQ5471A AUPQ547100A0 (en)	2000-02-07	2000-02-07	Liver selective therapy
PCT/AU2000/001337 WO2001032162A1 (en)	1999-11-03	2000-11-01	Liver selective therapy

Publications (2)

Publication Number	Publication Date
NO20021976D0 NO20021976D0 (en)	2002-04-25
NO20021976L true NO20021976L (en)	2002-06-19

Family

ID=27158192

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20021976A NO20021976L (en)	1999-11-03	2002-04-25	Selective liver therapy

Country Status (10)

Country	Link
US (3)	US20020160044A1 (en)
EP (1)	EP1242064A4 (en)
JP (1)	JP2003513036A (en)
KR (1)	KR20020063174A (en)
CN (1)	CN1387430A (en)
CA (1)	CA2389616A1 (en)
IL (1)	IL149422A0 (en)
NO (1)	NO20021976L (en)
NZ (1)	NZ518707A (en)
WO (1)	WO2001032162A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020183383A1 (en) *	2001-02-27	2002-12-05	Rene Belder	Pharmaceutical compositions
JP2005245667A (en) *	2004-03-03	2005-09-15	Koninkl Philips Electronics Nv	Medicine administration design system
WO2009095934A1 (en) *	2008-01-30	2009-08-06	Lupin Limited	Modified release formulations of hmg coa reductase inhibitors
HK1214752A1 (en)	2013-03-15	2016-08-05	Cedars-Sinai Medical Center	Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9289418B2 (en)	2013-03-15	2016-03-22	Cedars-Sinai Medical Center	Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
EP3179983A4 (en)	2014-08-13	2018-01-10	Cedars-Sinai Medical Center	Anti-methanogenic compositions and uses thereof
EP3277274B1 (en)	2015-04-01	2024-06-12	Cedars-Sinai Medical Center	Anti-methanogenic lovastatin analogs or derivatives and uses thereof
CN108057032B (en) *	2018-01-30	2020-06-05	中国人民解放军第二军医大学第二附属医院	Application of alverine in the preparation of drugs for preventing or treating portal hypertension

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4397786A (en) *	1981-11-23	1983-08-09	Merck & Co., Inc.	Method of preparing statine and derivatives
US4663310A (en) *	1984-04-04	1987-05-05	Merck & Co., Inc.	Renin inhibitors containing 2-substituted statine
DE3512128A1 (en) *	1985-04-03	1986-10-09	Merck Patent Gmbh, 6100 Darmstadt	PEPTIDE
US4976967A (en) *	1987-08-03	1990-12-11	Merck & Co., Inc.	Resin modulated drug delivery device for the delivery of HMG-CoA reductase inhibitor salts
US4876364A (en) *	1987-09-03	1989-10-24	Merck & Co., Inc.	Hydrogenation process for the formation of 4A,5-dihydro HMG-CoA reductase inhibitors
US4831165A (en) *	1987-09-03	1989-05-16	Merck & Co., Inc.	Hydrogenation process for the formation of 3,4-dihydro HMG-CoA reductase inhibitors
US4864035A (en) *	1987-09-03	1989-09-05	Merck & Co., Inc.	Hydrogenation process for the formation of tetrahydro HMG-CoA reductase inhibitors
US4826999A (en) *	1987-09-03	1989-05-02	Merck & Co., Inc.	Hydrogenation process for the formation of 3,5-dihydro HMG-CoA reductase inhibitors
US4855456A (en) *	1988-02-29	1989-08-08	Merck & Co., Inc.	Intermediates for 6-alpha-hydroxymethyl HMG-CoA reductase inhibitors
US4894466A (en) *	1988-02-29	1990-01-16	Merck & Co., Inc.	Intermediates and processes for β-6-hydroxymethyl HMG-CoA reductable inhibitors
US5021453A (en) *	1988-03-02	1991-06-04	Merck & Co., Inc.	3-keto HMG-CoA reductase inhibitors
EP0331250B1 (en) *	1988-03-02	1994-04-13	Merck & Co. Inc.	Antihypercholesterolemic agents
US4873345A (en) *	1988-09-29	1989-10-10	Merck & Co., Inc.	Process for the preparation of 5'-oxa, 5'-thia, 5'-aza HMG-CoA reductase inhibitors
US4921974A (en) *	1988-09-29	1990-05-01	Merck & Co., Inc.	Intermediates and processes in the preparation of 5-oxygenated HMG-COA reductase inhibitors
US4866186A (en) *	1988-06-30	1989-09-12	Merck & Co., Inc.	Process for the formation of 6-desmethyl-6-exo-methylene derivatives of lovastatin and analogs thereof
US5376383A (en) *	1988-11-21	1994-12-27	Merck & Co., Inc.	Method for enhancing the lowering of plasma-cholesterol levels
US4997849A (en) *	1989-06-23	1991-03-05	Merck & Co., Inc.	Microbial transformation of simvastatin
US5059696A (en) *	1990-03-15	1991-10-22	Merck & Co., Inc.	Processes and intermediates for the preparation of 5-oxygenated hmg-coa reductase inhibitors
US5223415A (en) *	1990-10-15	1993-06-29	Merck & Co., Inc.	Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
US5159104A (en) *	1991-05-01	1992-10-27	Merck & Co., Inc.	Process to simvastatin ester
US5250435A (en) *	1991-06-04	1993-10-05	Merck & Co., Inc.	Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
US5543154A (en) *	1991-12-27	1996-08-06	Merck & Co., Inc.	Controlled release nifedipine delivery device
US5789442A (en) *	1996-01-18	1998-08-04	Schering Aktiengesellschaft	Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US20010006644A1 (en) *	1997-07-31	2001-07-05	David J. Bova	Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
IE970731A1 (en) *	1997-10-07	2000-10-04	Fuisz Internat Ltd	Product and method for the treatment of hyperlipidemia
US5916595A (en) *	1997-12-12	1999-06-29	Andrx Pharmaceutials, Inc.	HMG co-reductase inhibitor
US6242003B1 (en) *	2000-04-13	2001-06-05	Novartis Ag	Organic compounds

2000
- 2000-11-01 CN CN00815452A patent/CN1387430A/en active Pending
- 2000-11-01 KR KR1020027005700A patent/KR20020063174A/en not_active Ceased
- 2000-11-01 JP JP2001534367A patent/JP2003513036A/en active Pending
- 2000-11-01 CA CA002389616A patent/CA2389616A1/en not_active Abandoned
- 2000-11-01 WO PCT/AU2000/001337 patent/WO2001032162A1/en not_active Ceased
- 2000-11-01 IL IL14942200A patent/IL149422A0/en unknown
- 2000-11-01 NZ NZ518707A patent/NZ518707A/en not_active IP Right Cessation
- 2000-11-01 EP EP00972466A patent/EP1242064A4/en not_active Withdrawn
2002
- 2002-04-25 NO NO20021976A patent/NO20021976L/en not_active Application Discontinuation
- 2002-05-03 US US10/137,444 patent/US20020160044A1/en not_active Abandoned
2007
- 2007-06-26 US US11/819,278 patent/US20070269513A1/en not_active Abandoned
- 2007-06-26 US US11/819,279 patent/US20080242732A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20020160044A1 (en)	2002-10-31
EP1242064A1 (en)	2002-09-25
WO2001032162A1 (en)	2001-05-10
CN1387430A (en)	2002-12-25
NZ518707A (en)	2003-10-31
US20070269513A1 (en)	2007-11-22
NO20021976D0 (en)	2002-04-25
CA2389616A1 (en)	2001-05-10
EP1242064A4 (en)	2005-02-09
US20080242732A1 (en)	2008-10-02
JP2003513036A (en)	2003-04-08
IL149422A0 (en)	2002-11-10
KR20020063174A (en)	2002-08-01

Publication	Publication Date	Title
DK1637127T3 (en)	2014-08-04	THERAPEUTIC MICROSUM
ID27841A (en)	2001-04-26	THERAPEUTIC BIARILS
DE60008674D1 (en)	2004-04-08	Funkwegführungssystem
DE60018571T8 (en)	2006-04-27	HERNIENPROTHESE
DE122007000064I2 (en)	2010-03-25	Erythropoietinkonjugate
DE10084676T1 (en)	2003-04-30	Einmallanzettvorrichtung
DE60013454D1 (en)	2004-10-07	WEKZEUGMASCHINE
ATA51899A (en)	2002-04-15	handstamp
DE60009430D1 (en)	2004-05-06	Türtülle
PT1235558E (en)	2006-09-29	THERAPEUTIC AGENTS
DE60034061D1 (en)	2007-05-03	4-pyrimidinyl-N-acyl-L-PHENYLANINE
DE60001283D1 (en)	2003-03-06	Celluloseetherfilme
DE60028351D1 (en)	2006-07-06	HAUTPFLEGETÜCHLEIN
DE60020883D1 (en)	2005-07-21	4-PYRIDINYL-N-ACYL-L-PHENYLALANINE
DE60015794D1 (en)	2004-12-16	KOMPOSITVERSCHLUSSKAPPE
DE60044218D1 (en)	2010-05-27	em
DE60012888D1 (en)	2004-09-16	MEVINOLINDERIVATE
ID27526A (en)	2001-04-12	TURUNAN II KUINOLIN-4-IL
DE60005322D1 (en)	2003-10-23	STAPELHUBVORRICHTUNG
DE69934828D1 (en)	2007-02-22	GATE-biasing
NO20021976L (en)	2002-06-19	Selective liver therapy
DE60001471D1 (en)	2003-04-03	4-Hydroxyisothiazolverbindungen
DE59906520D1 (en)	2003-09-11	EXZENTERZAHNRADGETRIEBE
DE19983890T1 (en)	2002-03-07	Ventiltaktgebungsjustiereinrichtung
DE60012398D1 (en)	2004-09-02	Alkylformamidtenside

Legal Events

Date	Code	Title	Description
2010-06-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application